TCBP TC BioPharm (Holdings) Plc: מכפיל מחיר להכנסות עתידי

The forward P/S ratio allows for an assessment of the asset's value dynamics, with 0.20 serving as the current value of the indicator. TC Biopharm revenues will be based on the implementation of gamma-delta T-cell therapy against leukemia. The company's innovative approach simplifies the mass application of cancer immunotherapy. The stability of R&D processes is guaranteed through a system of grants and the retention of key immunologists.

Forward P/S measures the market value of TC Biopharm relative to expected sales volume, allowing for an assessment of investor confidence in management's long-term strategy during the intervals between earnings reports. The trend of this forward revenue multiple reflects the speculative premium on TC Biopharm capital, which depends directly on the commercialization prospects of its available allogeneic gamma-delta T-cell based cancer therapy.